Evinacumab: Who Benefits From ANGPTL3 Cholesterol

How does evinacumab target the protein behind cholesterol gene-editing research?

The latest cholesterol gene-editing coverage raises a practical question: what treatments already act on the same biological target? Experimental CTX310 aims to switch off the ANGPTL3 gene in liver cells. Evinacumab, marketed as Evkeeza, acts on the resulting protein instead. The approaches share a target but have different delivery methods, treatment schedules and evidence requirements. [Cleveland Clinic research report](https://newsroom.clevelandclinic.org/2026/08/28/cleveland-clinic-first-in-human-trial-of-crispr-gene-editing-therapy-shown-to-safely-and-continuously-lower-cholesterol-and-triglycerides-after-one-year).

This distinction matters for people with homozygous familial hypercholesterolemia, or HoFH, a rare inherited disorder that causes extremely high LDL cholesterol and can produce cardiovascular disease early in life. Evinacumab can lower LDL even when LDL-receptor function is severely impaired, giving clinicians another treatment pathway when existing medicines leave cholesterol dangerously elevated. [FDA approval overview](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol-0).

What did the randomized evinacumab trial establish?

The ELIPSE HoFH trial, published in the New England Journal of Medicine in 2020, randomly assigned 65 patients to intravenous evinacumab or placebo alongside existing treatment. At 24 weeks, LDL cholesterol fell by 47.1% from baseline in the evinacumab group and rose by 1.9% with placebo. The difference between groups was 49.0 percentage points. Participants began with markedly elevated LDL despite their background therapy. [Raal and colleagues](https://www.nejm.org/doi/full/10.1056/NEJMoa2004215).

These findings establish an effect on cholesterol levels. The study's size, duration and primary endpoint do not establish a corresponding percentage reduction in heart attacks or strokes. Its results also cannot determine whether evinacumab or gene editing is preferable: that would require evidence addressing comparable patients, clinical outcomes and safety. Regeneron Pharmaceuticals funded the trial. [ELIPSE HoFH publication](https://www.nejm.org/doi/full/10.1056/NEJMoa2004215).

Who can receive evinacumab, and what does treatment involve?

The FDA label revised in September 2025 specifies use alongside diet, exercise and other LDL-lowering therapies. Infusions take approximately 60 minutes and are repeated every four weeks. This indication concerns a specific inherited disorder; it does not make evinacumab a routine treatment for everyone with elevated cholesterol. [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761181s002lbl.pdf).

Treatment planning must account for infusion visits and safety monitoring. Serious allergic reactions, including anaphylaxis, can occur. Reported adverse effects include nausea, dizziness and influenza-like illness. Animal findings also indicate potential fetal harm, making pregnancy planning an important discussion before treatment. These considerations remain relevant even when LDL responds strongly. [FDA safety information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761181s002lbl.pdf).